Table 3 Associations between CN expression, clinical parameters and overall survival
From: Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer
Clinical parameters | Overall survival (months) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total type | Clear-cell carcinoma | Serous carcinoma | Papillary serous cystadenocarcinoma | |||||||||||||
N | Mean | 95%CI | p-value | N | Mean | 95%CI | p-value | N | Mean | 95%CI | p-value | N | Mean | 95%CI | p-value | |
CN | ||||||||||||||||
≦50 | 24 | 96.73 | 76.00, 117.46 | 0.53 | 7 | 73.57 | 53.15, 93.99 | 0.73 | 7 | 69.29 | 34.03, 104.54 | 0.03* | 10 | 73.33 | 59.06, 87.61 | 0.27 |
>50 | 17 | 63.24 | 49.45, 77.02 | 10 | 69.8 | 52.34, 87.26 | 2 | 22.00 | 10.24, 33.76 | 5 | 59.4 | 39.98, 78.82 | ||||
Age (years) | ||||||||||||||||
< 50 | 26 | 140.79 | 106.30, 175.28 | 0.30 | 10 | 79.56 | 65.43, 93.69 | 0.18 | 7 | 118.88 | 52.82, 184.93 | 0.63 | 9 | 73.44 | 60.56, 86.33 | 0.91 |
≧50 | 24 | 86.20 | 67.27, 105.12 | 9 | 60.40 | 40.08, 80.72 | 8 | 72.71 | 40.43, 105.00 | 7 | 63.00 | 44.19, 81.86 | ||||
Pathological stage | ||||||||||||||||
I~II | 29 | 160.80 | 133.60, 188.00 | < 0.01* | 9 | 87.56 | 81.19, 93.92 | 0.03* | 10 | 143.50 | 91.66, 195.34 | < 0.01* | 10 | 70.20 | 56.49, 83.91 | 0.26 |
III~IV | 20 | 53.05 | 40.27, 65.83 | 9 | 55.67 | 34.21, 77.12 | 5 | 31.80 | 24.86, 38.74 | 6 | 65.17 | 46.86, 83.47 | ||||
Tumor size (mm3) | ||||||||||||||||
< 395 | 26 | 123.50 | 91.08, 155.92 | 0.71 | 5 | 66.60 | 40.40, 92.80 | 0.81 | 12 | 110.33 | 61.84, 158.82 | 0.67 | 9 | 71.33 | 57.58, 85.09 | 0.98 |
≧395 | 24 | 68.00 | 56.19, 79.81 | 14 | 70.50 | 55.05, 85.95 | 3 | 48.00 | 22.28, 73.72 | 7 | 65.71 | 47.24, 84.19 | ||||
LN metastasis | ||||||||||||||||
No | 31 | 158.09 | 131.28, 184.90 | < 0.01* | 11 | 82.91 | 72.21, 93.61 | 0.02* | 10 | 143.50 | 91.66, 195.34 | < 0.01* | 10 | 70.20 | 56.49, 83.91 | 0.26 |
Yes | 19 | 50.95 | 38.08, 63.82 | 8 | 51.00 | 28.58, 73.43 | 5 | 31.80 | 24.86, 38.74 | 6 | 65.17 | 46.86, 83.47 | ||||
Distant metastasis | ||||||||||||||||
No | 48 | 127.95 | 103.85, 152.05 | 0.88 | 18 | 82.46 | 76.09, 88.82 | 0.49 | 15 | 106.27 | 63.19, 149.34 | ─ | 15 | 69.53 | 57.31, 81.76 | 0.39 |
Yes | 2 | 75.00 | 66.68, 83.32 | 1 | 81.00 | 81.00, 81.00 | 0 | ─ | ─ | 1 | 69.00 | 69.00, 69.00 | ||||
Ascites | ||||||||||||||||
No | 26 | 134.35 | 101.53, 167.16 | 0.59 | 10 | 65.50 | 49.72, 81.28 | 0.84 | 11 | 113.46 | 60.45, 166.46 | 0.65 | 5 | 80.40 | 74.09, 86.71 | 0.19 |
Yes | 24 | 66.34 | 54.61, 78.06 | 9 | 70.56 | 50.00, 91.11 | 4 | 55.00 | 32.34, 77.66 | 11 | 63.64 | 48.48, 78.79 | ||||
Chemotherapeutic response | ||||||||||||||||
No | 2 | 66.00 | 38.28, 93.72 | 0.99 | 1 | 46.00 | 46.00, 46.00 | 0.27 | 0 | ─ | ─ | ─ | 1 | 86.00 | 86.00, 86.00 | 0.47 |
Yes | 37 | 91.51 | 75.18, 107.84 | 15 | 70.60 | 55.21, 85.99 | 10 | 66.40 | 37.16, 95.64 | 12 | 85.75 | 78.54, 92.96 | ||||
Chemotherapeutic resistance | ||||||||||||||||
No | 21 | 125.89 | 110.57, 141.23 | < 0.01* | 5 | 88.56 | 82.19, 94.92 | 0.01* | 5 | 123.00 | 87.94, 158.06 | 0.24 | 11 | 77.12 | 68.46, 85.77 | 0.02* |
Yes | 11 | 52.27 | 37.78, 66.76 | 5 | 49.00 | 26.58, 71.43 | 1 | 59.00 | 59.00, 59.00 | 5 | 49.60 | 27.15, 72.05 | ||||
CA125 (U/ml) | ||||||||||||||||
< 324 | 24 | 120.68 | 85.63, 155.73 | 0.49 | 11 | 77.27 | 63.36, 91.19 | 0.41 | 5 | 113.89 | 55.42, 172.36 | 0.43 | 8 | 74.18 | 59.48, 88.87 | 0.56 |
≧324 | 24 | 71.67 | 61.36, 81.87 | 7 | 59.86 | 36.36, 83.36 | 9 | 50.40 | 29.89, 70.90 | 8 | 63.88 | 47.47, 80.28 | ||||
CA19–9 (U/ml) | ||||||||||||||||
< 21.55 | 24 | 130.61 | 94.49, 166.73 | 0.75 | 8 | 81.25 | 63.37, 99.13 | 0.21 | 8 | 134.29 | 64.96, 203.61 | 0.22 | 8 | 76.88 | 67.98, 85.77 | 0.60 |
≧21.55 | 23 | 99.98 | 80.42, 119.54 | 9 | 64.56 | 47.29, 81.82 | 7 | 65.75 | 34.39, 97.11 | 7 | 59.00 | 37.42, 80.58 | ||||
CA72–4 (U/ml) | ||||||||||||||||
< 7.89 | 25 | 164.61 | 134.70, 194.52 | < 0.01* | 8 | 86.56 | 80.19, 92.92 | 0.01* | 9 | 134.56 | 76.93, 192.18 | 0.10 | 8 | 69.13 | 52.32, 85.93 | 0.26 |
≧7.89 | 24 | 56.17 | 45.78, 66.56 | 10 | 53.67 | 32.21, 75.12 | 6 | 42.83 | 29.35, 56.31 | 8 | 67.88 | 53.35, 82.40 | ||||
AFP (ng/mL) | ||||||||||||||||
< 2.9 | 25 | 142.27 | 108.32, 176.22 | 0.32 | 7 | 73.00 | 55.03, 90.97 | 0.60 | 6 | 115.00 | 57.28, 172.72 | 0.54 | 12 | 81.75 | 74.54, 88.96 | 0.37 |
≧2.9 | 24 | 87.09 | 67.74, 106.44 | 11 | 66.57 | 48.66, 84.48 | 9 | 70.83 | 32.42, 109.25 | 4 | 64.01 | 50.29, 77.73 | ||||
CEA (ng/mL) | ||||||||||||||||
< 1.48 | 24 | 141.13 | 106.79, 175.46 | 0.28 | 10 | 78.13 | 62.51, 93.74 | 0.45 | 8 | 132.43 | 61.69, 203.16 | 0.28 | 6 | 72.33 | 62.58, 82.09 | 0.95 |
≧1.48 | 24 | 85.70 | 65.99, 105.41 | 8 | 62.80 | 44.44, 81.16 | 7 | 66.63 | 36.26, 96.99 | 9 | 63.56 | 45.83, 81.28 | ||||